Healthcare Economist November 5, 2025
That is the question a new paper by Chambers et al. (2025) aims to answer. The authors use data from the Specialty Drug Evidence and Coverage (SPEC) Database, which contains coverage policies related to specialty pharmacy for a large number of US health plans, to examine how n=25 cell and gene therapies are being covered by US commercial health plans. With these data, they find that:
Among 541 indication-plan pair...







